European Primary Care Cardiovascular Society
A study using data of millions of patients showed that there are no differences in effectiveness between drug classes when initiating monotherapy for hypertension, with the exception of lower risk of MI, HHF and stroke with thiazide or thiazide-like diuretics when compared to ACEi.
A randomized clinical trial of hypertensive patients demonstrates that ingestion of hypertension medication at bedtime reduces asleep ABP and CVD event risk compared to ingestion upon awakening.
Read the abstract of the EPCCS Guidance on diagnosis and management of hypertension in primary care in Slovak.
Read the abstract of the EPCCS Guidance on diagnosis and management of hypertension in primary care in Ukrainian.
Read the abstract of the EPCCS Guidance on diagnosis and management of hypertension in primary care in Greek.
Read the abstract of the EPCCS Guidance on diagnosis and management of hypertension in primary care in French.
ESC 2019 A stepped-wedge cluster randomized controlled trial showed that a salt-substitution strategy in 6 villages in Peru lowered blood pressure and reduced incidence of hypertension by half.
ESC 2019 In community-based studies in Colombia and Malaysia, HOPE-4 achieved reduced CV risk, better treatment adherence and healthier behavior with an intervention that targeted previously identified barriers to care.
Download the EPCCS Practical Guidance Document, which provides a brief scientific background on the need for and practical guidance on management of hypertension, including when to start treatment and which blood pressure target should be used for a given patient. The document focusses on challenges faced in clinical reality.
In a large cohort study of 1.3 million participants, both systolic and diastolic hypertension were associated with composite of MI, ischemic stroke and hemorrhagic stroke, independent of thresholds defining hypertension.
ESC HF 2019 Addition of patiromer to spironolactone showed that a higher percentage of patients remained on spironolactone vs. those on placebo and spironolactone at the start, with no difference between HF or non-HF.
An analysis of the ADVANCE study shows that the treatment effect of perindopril-indapamide in patients with diabetes is independent of SBP, DBP or 10-year ASCVD risk at baseline.